Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522

Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kuemmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Zhu Y, Pan W, Tryfonidis K, Karantza V, O'Shaughnessy J (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Publisher: WILEY

City/Town: HOBOKEN

Pages Range: 117-118

Conference Proceedings Title: ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Authors with CRIS profile

Involved external institutions

Queen Mary, University of London United Kingdom (GB) Vall d'Hebron Institute of Oncology: VHIO Spain (ES) Yale University United States (USA) (US) Kliniken Essen-Mitte Germany (DE) Karolinska University Hospital / Karolinska Universitetssjukhuset Sweden (SE) Philipps-Universität Marburg Germany (DE) Sungkyunkwan University (SKKU) Korea, Republic of (KR) Westmead Hospital Australia (AU) Klinikum der Universität München Germany (DE) Hokkaido Cancer Society Japan (JP) HELIOS Kliniken Germany (DE) Champalimaud Foundation / Fundação Champalimaud Portugal (PT) The US Oncology Network United States (USA) (US) Instituto Português de Oncologia Francisco Gentil (IPO) / Portuguese Oncology Institute Portugal (PT) Centre Jean-Perrin (UNICANCER) France (FR) Seoul National University (SNU) / 서울대학교 Korea, Republic of (KR) University of Ulsan / 울산대학교 Korea, Republic of (KR) Hospital Universitario Ramón y Cajal Spain (ES) Royal North Shore Hospital (RNSH) Australia (AU) McGill University Canada (CA) Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD) United States (USA) (US) Baylor University (BU) United States (USA) (US) National University of Singapore (NUS) Singapore (SG) University of Texas Southwestern Medical Center (UT Southwestern) United States (USA) (US)

How to cite

APA:

Schmid, P., Cortes, J., Dent, R., Pusztai, L., Mcarthur, H., Kuemmel, S.,... O'Shaughnessy, J. (2022). Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (pp. 117-118). HOBOKEN: WILEY.

MLA:

Schmid, Peter, et al. "Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522." Proceedings of the ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY HOBOKEN: WILEY, 2022. 117-118.

BibTeX: Download